嚢胞性線維症（CF）治療薬の世界市場レポート 2025年

嚢胞性線維症（CF）治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.3％で114億2,000万米ドルに成長します。予測期間における成長の要因としては、調査対象患者数の増加、新規治療薬に対する規制当局の承認、個別化医療への注力、バイオマーカー研究への投資の増加、新生児スクリーニングプログラムの拡大、ヘルスケア政策支援などが挙げられます。予測期間における主な動向としては、CFTRモジュレーターの拡大、遺伝子編集技術、早期介入戦略、診断技術の改善、遠隔医療と遠隔モニタリング、ヘルスケアのデジタル化、慢性疾患管理などが挙げられます。

嚢胞性線維症（CF）に罹患する人口の増加が予測され、嚢胞性線維症治療薬市場拡大の原動力となります。肺、消化器系、その他の臓器に影響を及ぼす遺伝性疾患であるCFでは、肺粘液を薄め、排出しやすくするための治療介入が必要です。嚢胞性線維症を患う人の増加に伴い、効果的なCF治療薬の需要は急増すると予想されています。その一例として、嚢胞性線維症（CF）財団が2022年7月に発表した報告書によると、CF患者の急増が明らかになり、米国では約4万人、世界では10万5,000人以上が罹患していると診断されています。このようなCF患者の増加は、嚢胞性線維症治療薬市場の成長を促す重要な原動力となっています。

個別化医療と標的療法への注目の高まりは、嚢胞性線維症治療薬市場を前進させる構えです。個別化医療は、患者固有の遺伝子構成、タンパク質、その他の生物学的要因に基づいて医療を調整するもので、正確で個別化された治療を可能にします。このアプローチは、CFの根底にある複雑な遺伝子変異を理解するのに役立ち、各患者の異なる遺伝子プロファイルに沿ったカスタマイズされた治療計画への道を開きます。特に、個別化医療連合（Personalized Medicine Coalition）による調査報告書『The Scope and Significance of Progress in 2022』では、米国食品医薬品局が2022年に12の個別化医薬品を承認することが強調されており、これは新たに承認される分子生物学的治療薬全体の約34%に相当します。このような個別化医療と標的療法への注目の高まりが、嚢胞性線維症治療薬市場拡大の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の嚢胞性線維症（CF）治療薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の嚢胞性線維症（CF）治療薬市場：成長率分析
• 世界の嚢胞性線維症（CF）治療薬市場の実績：規模と成長, 2019-2024
• 世界の嚢胞性線維症（CF）治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の嚢胞性線維症（CF）治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の嚢胞性線維症（CF）治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 膵臓酵素サプリメント
• 粘液溶解薬
• 気管支拡張薬
• CFTRモジュレーター
• 世界の嚢胞性線維症（CF）治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 吸入
• 世界の嚢胞性線維症（CF）治療薬市場：治療方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• デバイス
• 世界の嚢胞性線維症（CF）治療薬市場膵酵素サプリメントの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リパーゼ
• アミラーゼ
• プロテアーゼ
• 世界の嚢胞性線維症（CF）治療薬市場：粘液溶解薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドルナーゼアルファ（プルモザイム）
• 高張食塩水
• 世界の嚢胞性線維症（CF）治療薬市場：気管支拡張薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 短時間作用型ベータ刺激薬（SABA）
• 長時間作用型ベータ刺激薬（LABA）
• 抗コリン薬
• 世界の嚢胞性線維症（CF）治療薬市場：CFTRモジュレーターのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• イバカフトール
• ルマカフトールまたはイバカフトール（オルカンビ）
• テザカフトールまたはイバカフトール（シムデコ）
• エレキサカフターまたはテザカフターまたはイバカフター

第7章 地域別・国別分析

• 世界の嚢胞性線維症（CF）治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の嚢胞性線維症（CF）治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 嚢胞性線維症（CF）治療薬市場：競合情勢
• 嚢胞性線維症（CF）治療薬市場：企業プロファイル
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Vertex Pharmaceuticals Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • Chiesi Farmaceutici SpA Overview, Products and Services, Strategy and Financial Analysis
  • PTC Therapeutics LIMITED Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Genentech Inc.
• Alaxia
• AstraZeneca
• Beyond Air Inc.
• Pfizer Inc.
• Alcresta Therapeutics Inc.
• Laurent Pharmaceuticals
• Nestle HealthScience
• Pharmaxis
• Bayer AG
• AbbVie Inc.
• Novartis AG
• Arcturus Therapeutics Holdings Inc.
• Arrowhead Pharmaceuticals Inc
• ProQR Therapeutics N.V.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 嚢胞性線維症（CF）治療薬市場2029：新たな機会を提供する国
• 嚢胞性線維症（CF）治療薬市場2029：新たな機会を提供するセグメント
• 嚢胞性線維症（CF）治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cystic fibrosis (CF) therapeutics encompasses medications designed to thin and facilitate the coughing up of lung mucus in individuals with this inherited disorder. CF causes severe damage to the lungs, digestive system, and other organs.

The primary drug classes for CF therapeutics include pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators. Pancreatic enzyme supplements contain pancreatin or pancrelipase, a combination of lipase, amylase, and protease, produced by the pancreas. These supplements can be administered orally or through inhalation. The treatment methods for cystic fibrosis involve a combination of medications and devices to manage the condition effectively.

The cystic fibrosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides cystic fibrosis therapeutics market statistics, including cystic fibrosis therapeutics industry global market size, regional shares, competitors with a cystic fibrosis therapeutics market share, detailed cystic fibrosis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the cystic fibrosis therapeutics industry. This cystic fibrosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cystic fibrosis (CF) therapeutics market size has grown rapidly in recent years. It will grow from $7.54 billion in 2024 to $8.31 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to advancements in targeted therapies, growing understanding of CF genetics, patient advocacy and awareness, government support for research, orphan drug designations, incentives for rare disease research.

The cystic fibrosis (CF) therapeutics market size is expected to see strong growth in the next few years. It will grow to $11.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to rise in C patient population, regulatory approvals for novel therapies, focus on personalized medicine, increasing investment in biomarker research, expanded newborn screening programs, healthcare policy support. Major trends in the forecast period include expansion of CFTR modulators, gene editing technologies, early intervention strategies, improved diagnostic techniques, telehealth and remote monitoring, healthcare digitalization, chronic disease management.

The projected increase in the population affected by cystic fibrosis (CF) is set to be a driving force behind the expansion of the cystic fibrosis therapeutics market. CF, an inherited condition impacting the lungs, digestive system, and other organs, necessitates therapeutic interventions to thin lung mucus, making it easier to expel. As the number of individuals suffering from cystic fibrosis rises, the demand for effective CF therapeutics is expected to soar. An illustrative example is a report released by The Cystic Fibrosis (CF) Foundation in July 2022, revealing a surge in CF cases, with almost 40,000 affected individuals in the United States and over 105,000 diagnosed worldwide. This escalation in CF patients is a significant driving factor fueling the cystic fibrosis therapeutics market growth.

The burgeoning emphasis on personalized medicine and targeted therapies is poised to drive the cystic fibrosis therapeutics market forward. Personalized medicine involves tailoring medical care based on patients' unique genetic makeup, proteins, and other biological factors, enabling precise and individualized treatments. This approach aids in comprehending the intricate genetic mutations underlying CF, paving the way for customized treatment plans aligned with each patient's distinct genetic profile. Notably, The Scope and Significance of Progress in 2022 report by the Personalized Medicine Coalition highlighted the US Food and Drug Administration's approval of 12 personalized medicines in 2022, constituting approximately 34% of all newly approved therapeutic molecular entities. This growing focus on personalized medicine and targeted therapies is a driving force behind the expansion of the cystic fibrosis therapeutics market.

Leading companies in the cystic fibrosis (CF) therapeutics market are developing innovative treatment and patient care solutions, such as the cystic fibrosis innovation hub network, to speed up research, enhance treatment options, and foster collaboration in the creation of new therapies for CF patients. The cystic fibrosis innovation hub network serves as a collaborative platform or initiative aimed at expediting the research and development of new treatments for cystic fibrosis (CF). For example, in October 2024, LifeArc, a UK-based charity and life sciences organization focused on translating scientific research into effective healthcare solutions, launched the UK's first Cystic Fibrosis Innovation Hub Network. This hub is designed to advance research and development for cystic fibrosis (CF) treatments, promoting collaboration among healthcare providers, researchers, and patients. Initiated as part of a larger effort to accelerate innovation in cystic fibrosis therapies, the hub concentrates on discovering new pathways for drug development and enhancing patient outcomes.

Key players within the cystic fibrosis (CF) therapeutics market are actively directing their efforts towards strategic investments aimed at expanding their presence and fortifying their market positions. Strategic investment in medical research encompasses a deliberate allocation of resources, expertise, and funding into scientific research endeavors with the primary objectives of advancing medical understanding, developing innovative treatments, and refining healthcare protocols. An exemplary instance of such strategic investment occurred in January 2023 when the Cystic Fibrosis Foundation (CF Foundation), a US-based non-profit organization dedicated to supporting diverse research initiatives for CF cure, announced a significant investment of up to $15 million in ReCode Therapeutics. ReCode, a US-based clinical-stage genetic medicines and biotechnology company, specializes in employing advanced delivery mechanisms to drive the next wave of messenger ribonucleic acid (mRNA) and gene correction therapeutics. This substantial investment is intended to facilitate the development of ReCode's inhaled mRNA-based therapeutic tailored for individuals with cystic fibrosis (CF), particularly those with genotypes unresponsive to approved cystic fibrosis transmembrane conductance regulator (CFTR) modulators.

In July 2024, Sionna Therapeutics, a US-based healthcare organization, acquired the rights to develop and commercialize several cystic fibrosis (CF) compounds from AbbVie Inc. for an undisclosed amount. This acquisition allows Sionna to focus on the commercialization of three specific compounds: ABBV-2222, ABBV-3067, and ABBV-2851, aimed at enhancing the efficiency of cystic fibrosis (CF) treatment. AbbVie Inc. is a US-based company specializing in cystic fibrosis (CF) therapeutics.

Major companies operating in the cystic fibrosis (CF) therapeutics market include Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Vertex Pharmaceuticals Incorporated, Chiesi Farmaceutici SpA, PTC Therapeutics LIMITED, Genentech Inc., Alaxia, AstraZeneca, Beyond Air Inc., Pfizer Inc., Alcresta Therapeutics Inc., Laurent Pharmaceuticals, Nestle HealthScience, Pharmaxis, Bayer AG, AbbVie Inc., Novartis AG, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc, ProQR Therapeutics N.V., Enterprise Therapeutics Ltd. , Corbus Pharmaceuticals Holdings Inc, Eloxx Pharmaceuticals , Translate Bio Inc, Zambon S.p.A

North America was the largest region in the cystic fibrosis (CF) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the cystic fibrosis (CF) therapeutics market during the forecast period. The regions covered in the cystic fibrosis (cf) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cystic fibrosis (cf) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cystic fibrosis (CF) therapeutics market includes revenues earned by entities by providing services that include administration of mucus thinner, airway clearance, and antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cystic Fibrosis (CF) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cystic fibrosis (cf) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cystic fibrosis (cf) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cystic fibrosis (cf) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Pancreatic Enzyme Supplements; Mucolytic; Bronchodilators; CFTR Modulators
• 2) By Route Of Administration: Oral; Inhaled
• 3) By Treatment Method: Medication; Devices
• Subsegments:
• 1) By Pancreatic Enzyme Supplements: Lipase; Amylase; Protease
• 2) By Mucolytics: Dornase Alfa (Pulmozyme); Hypertonic Saline
• 3) By Bronchodilators: Short-Acting Beta Agonists (SABAs); Long-Acting Beta Agonists (LABAs); Anticholinergics
• 4) By CFTR Modulators: Ivacaftor; Lumacaftor Or Ivacaftor (Orkambi); Tezacaftor Or Ivacaftor (Symdeko); Elexacaftor Or Tezacaftor Or Ivacaftor
• Companies Mentioned: Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche AG; Vertex Pharmaceuticals Incorporated; Chiesi Farmaceutici SpA; PTC Therapeutics LIMITED
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cystic Fibrosis (CF) Therapeutics Market Characteristics

3. Cystic Fibrosis (CF) Therapeutics Market Trends And Strategies

4. Cystic Fibrosis (CF) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cystic Fibrosis (CF) Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cystic Fibrosis (CF) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cystic Fibrosis (CF) Therapeutics Market Growth Rate Analysis
• 5.4. Global Cystic Fibrosis (CF) Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cystic Fibrosis (CF) Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cystic Fibrosis (CF) Therapeutics Total Addressable Market (TAM)

6. Cystic Fibrosis (CF) Therapeutics Market Segmentation

• 6.1. Global Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pancreatic Enzyme Supplements
• Mucolytic
• Bronchodilators
• CFTR Modulators
• 6.2. Global Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Inhaled
• 6.3. Global Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Devices
• 6.4. Global Cystic Fibrosis (CF) Therapeutics Market, Sub-Segmentation Of Pancreatic Enzyme Supplements, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lipase;
• Amylase
• Protease
• 6.5. Global Cystic Fibrosis (CF) Therapeutics Market, Sub-Segmentation Of Mucolytics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dornase Alfa (Pulmozyme)
• Hypertonic Saline
• 6.6. Global Cystic Fibrosis (CF) Therapeutics Market, Sub-Segmentation Of Bronchodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Short-Acting Beta Agonists (SABAs)
• Long-Acting Beta Agonists (LABAs)
• Anticholinergics
• 6.7. Global Cystic Fibrosis (CF) Therapeutics Market, Sub-Segmentation Of CFTR Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ivacaftor
• Lumacaftor Or Ivacaftor (Orkambi)
• Tezacaftor Or Ivacaftor (Symdeko)
• Elexacaftor Or Tezacaftor Or Ivacaftor

7. Cystic Fibrosis (CF) Therapeutics Market Regional And Country Analysis

• 7.1. Global Cystic Fibrosis (CF) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cystic Fibrosis (CF) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market

• 8.1. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cystic Fibrosis (CF) Therapeutics Market

• 9.1. China Cystic Fibrosis (CF) Therapeutics Market Overview
• 9.2. China Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cystic Fibrosis (CF) Therapeutics Market

• 10.1. India Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cystic Fibrosis (CF) Therapeutics Market

• 11.1. Japan Cystic Fibrosis (CF) Therapeutics Market Overview
• 11.2. Japan Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cystic Fibrosis (CF) Therapeutics Market

• 12.1. Australia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cystic Fibrosis (CF) Therapeutics Market

• 13.1. Indonesia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cystic Fibrosis (CF) Therapeutics Market

• 14.1. South Korea Cystic Fibrosis (CF) Therapeutics Market Overview
• 14.2. South Korea Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cystic Fibrosis (CF) Therapeutics Market

• 15.1. Western Europe Cystic Fibrosis (CF) Therapeutics Market Overview
• 15.2. Western Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cystic Fibrosis (CF) Therapeutics Market

• 16.1. UK Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cystic Fibrosis (CF) Therapeutics Market

• 17.1. Germany Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cystic Fibrosis (CF) Therapeutics Market

• 18.1. France Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cystic Fibrosis (CF) Therapeutics Market

• 19.1. Italy Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cystic Fibrosis (CF) Therapeutics Market

• 20.1. Spain Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cystic Fibrosis (CF) Therapeutics Market

• 21.1. Eastern Europe Cystic Fibrosis (CF) Therapeutics Market Overview
• 21.2. Eastern Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cystic Fibrosis (CF) Therapeutics Market

• 22.1. Russia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cystic Fibrosis (CF) Therapeutics Market

• 23.1. North America Cystic Fibrosis (CF) Therapeutics Market Overview
• 23.2. North America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cystic Fibrosis (CF) Therapeutics Market

• 24.1. USA Cystic Fibrosis (CF) Therapeutics Market Overview
• 24.2. USA Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cystic Fibrosis (CF) Therapeutics Market

• 25.1. Canada Cystic Fibrosis (CF) Therapeutics Market Overview
• 25.2. Canada Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cystic Fibrosis (CF) Therapeutics Market

• 26.1. South America Cystic Fibrosis (CF) Therapeutics Market Overview
• 26.2. South America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cystic Fibrosis (CF) Therapeutics Market

• 27.1. Brazil Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cystic Fibrosis (CF) Therapeutics Market

• 28.1. Middle East Cystic Fibrosis (CF) Therapeutics Market Overview
• 28.2. Middle East Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cystic Fibrosis (CF) Therapeutics Market

• 29.1. Africa Cystic Fibrosis (CF) Therapeutics Market Overview
• 29.2. Africa Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cystic Fibrosis (CF) Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Cystic Fibrosis (CF) Therapeutics Market Competitive Landscape
• 30.2. Cystic Fibrosis (CF) Therapeutics Market Company Profiles
  • 30.2.1. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Vertex Pharmaceuticals Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Chiesi Farmaceutici SpA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. PTC Therapeutics LIMITED Overview, Products and Services, Strategy and Financial Analysis

31. Cystic Fibrosis (CF) Therapeutics Market Other Major And Innovative Companies

• 31.1. Genentech Inc.
• 31.2. Alaxia
• 31.3. AstraZeneca
• 31.4. Beyond Air Inc.
• 31.5. Pfizer Inc.
• 31.6. Alcresta Therapeutics Inc.
• 31.7. Laurent Pharmaceuticals
• 31.8. Nestle HealthScience
• 31.9. Pharmaxis
• 31.10. Bayer AG
• 31.11. AbbVie Inc.
• 31.12. Novartis AG
• 31.13. Arcturus Therapeutics Holdings Inc.
• 31.14. Arrowhead Pharmaceuticals Inc
• 31.15. ProQR Therapeutics N.V.

32. Global Cystic Fibrosis (CF) Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cystic Fibrosis (CF) Therapeutics Market

34. Recent Developments In The Cystic Fibrosis (CF) Therapeutics Market

35. Cystic Fibrosis (CF) Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Cystic Fibrosis (CF) Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cystic Fibrosis (CF) Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cystic Fibrosis (CF) Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer